Lv2
138 积分 2025-12-23 加入
Generation of Virtual Populations for Quantitative Systems Pharmacology Through Advanced Sampling Methods
16天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
22天前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
28天前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
30天前
已完结
Exposure-Response Relationships between the Factor B Inhibitor Iptacopan and Complement Biomarkers in Healthy Volunteers and Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G) or IgA Nephropathy (IgAN)
1个月前
已完结
Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation
3个月前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
3个月前
已完结
Exposure-Response Relationships between the Factor B Inhibitor Iptacopan and Complement Biomarkers in Healthy Volunteers and Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G) or IgA Nephropathy (IgAN)
3个月前
已完结
Human Alternative Complement Pathway: Membrane-Associated Sialic Acid Regulates the Competition between B and β1H for Cell-Bound C3b
3个月前
已完结
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface
3个月前
已完结
皖公网安备34019202002308
